Cardiorenal care coordination: holistic patient care opportunities in the primary care setting for patients with chronic kidney disease and atherosclerotic cardiovascular disease

References

• U.S. Renal Data System. USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2022.
   Google Scholar
• Bakris G. Use of SGLT-2 inhibitors to treat chronic kidney disease in primary care. J Fam Pract. 2022;71:S88–S93. doi: 10.12788/jfp.0389
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. 2021. [cited 2022 Dec 14]. Available from: https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
   Google Scholar
• de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in Chronic kidney disease: a consensus report by the American diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022 Dec 1;45(12):3075–3090. doi: 10.2337/dci22-0027
   PubMed Web of Science ®Google Scholar
• Garg D, Naugler C, Bhella V, et al. Chronic kidney disease in type 2 diabetes: does an abnormal urine albumin-to-creatinine ratio need to be retested? Can Fam Physician. 2018 Oct;64(10):e446–e452.
   PubMed Web of Science ®Google Scholar
• Wang M, Peter SS, Chu CD, et al. Analysis of specialty nephrology care among patients with Chronic kidney disease and high risk of disease progression. JAMA Netw Open. 2022;5(8):e2225797–e2225797. doi: 10.1001/jamanetworkopen.2022.25797
   PubMed Web of Science ®Google Scholar
• Mathew RO, Bangalore S, Lavelle MP, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017;91(4):797–807. doi: 10.1016/j.kint.2016.09.049
   PubMed Web of Science ®Google Scholar
• Rosenblit P. Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition. Curr Diab Rep. 2019;19(8):1–20. doi: 10.1007/s11892-019-1178-6
   PubMed Web of Science ®Google Scholar
• Sajja A, Li H-F, Spinelli KJ, et al. A simplified approach to identification of risk status in patients with atherosclerotic cardiovascular disease. Am J Prev Cardiol. 2021 Sep 01;7:100187.
   PubMedGoogle Scholar
• Vasan RS, Enserro DM, Xanthakis V, et al. Temporal trends in the remaining lifetime risk of cardiovascular disease among middle-aged adults across 6 decades: the Framingham study. Circulation. 2022;145(17):1324–1338. doi: 10.1161/CIRCULATIONAHA.121.057889
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of cardiology/American heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895–e1032.
   PubMed Web of Science ®Google Scholar
• Amdur RL, Feldman HI, Dominic EA, et al. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study. Am J Kidney Dis. 2019 Mar;73(3):344–353. doi: 10.1053/j.ajkd.2018.09.012
   PubMed Web of Science ®Google Scholar
• Amdur RL, Feldman HI, Gupta J, et al. Inflammation and progression of CKD: the CRIC study. Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1546–1556. doi: 10.2215/CJN.13121215
   PubMed Web of Science ®Google Scholar
• Bajaj A, Xie D, Cedillo-Couvert E, et al. Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD. Am J Kidney Dis. 2019 Jun;73(6):827–836. doi: 10.1053/j.ajkd.2018.11.010
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Amann K, Bangalore S, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019 Oct 8;74(14):1823–1838. doi: 10.1016/j.jacc.2019.08.1017
   PubMed Web of Science ®Google Scholar
• Poudel B, Rosenson RS, Bittner V, et al. Atherosclerotic cardiovascular disease events in adults with CKD taking a moderate- or high-intensity statin: the Chronic renal insufficiency cohort (CRIC) study. Kidney Med. 2021 Sep;3(5):722–731.e1. doi: 10.1016/j.xkme.2021.04.008
   PubMedGoogle Scholar
• Eknoyan G, Lameire N, Eckardt K, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan 1;3(1):5–14.
   Web of Science ®Google Scholar
• Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management. JAMA. 2019;322(13):1294–1304. doi: 10.1001/jama.2019.14745
   PubMed Web of Science ®Google Scholar
• Pagidipati NJ, Nelson AJ, Kaltenbach LA, et al. Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial. JAMA. 2023;329(15):1261–1270. doi: 10.1001/jama.2023.2854
   PubMed Web of Science ®Google Scholar
• Stellefson M, Dipnarine K, Stopka C. The chronic care model and diabetes management in US primary care settings: a systematic review. Prev Chronic Dis. 2013;10:E26. doi: 10.5888/pcd10.120180
   PubMed Web of Science ®Google Scholar
• Duan-Porter W, Ullman K, Majeski B, et al. Care coordination models and tools: a systematic review and key informant interviews [internet]. (WA) D.C: Department of Veteran Affairs; 2020.
   Google Scholar
• Wong ND, Budoff MJ, Ferdinand K, et al. Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive cardiology clinical practice statement. Am J Prev Cardiol. 2022 Jun;10:100335.
   PubMedGoogle Scholar
• Gregg LP, Hedayati SS. Management of traditional cardiovascular risk factors in CKD: what are the data? Am J Kidney Dis. 2018 Nov;72(5):728–744. doi: 10.1053/j.ajkd.2017.12.007
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Jones CR, Daratha KB, et al. Incidence of Chronic kidney disease among adults with diabetes, 2015-2020. N Engl J Med. 2022 Oct 13;387(15):1430–1431. doi: 10.1056/NEJMc2207018
   PubMed Web of Science ®Google Scholar
• Kushner PR, Cavender MA, Mende CW. Role of primary care clinicians in the management of patients with type 2 diabetes and cardiorenal diseases. Clin Diabetes. 2022 Fall;40(4):401–412. doi: 10.2337/cd21-0119.
   PubMedGoogle Scholar
• Branch M, German C, Bertoni A, et al. Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial. J Diabetes Complications. 2019 Jul;33(7):468–472. doi: 10.1016/j.jdiacomp.2019.04.004
   PubMed Web of Science ®Google Scholar
• Chaudhry RI, Mathew RO, Sidhu MS, et al. Detection of atherosclerotic cardiovascular disease in patients with advanced Chronic kidney disease in the cardiology and nephrology communities. Cardiorenal Med. 2018;8(4):285–295. doi: 10.1159/000490768
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Getting to goal: overcoming therapeutic inertia in diabetes care; 2022. [cited 2022 Dec 14]. Available from: https://www.therapeuticinertia.diabetes.org/about-therapeutic-inertia
   Google Scholar
• Khatib R, Glowacki N, Lauffenburger J, et al. Race/Ethnic differences in atherosclerotic cardiovascular disease risk factors among patients with hypertension: analysis from 143 primary care clinics. Am J Hypertens. 2021;34(9):948–955. doi: 10.1093/ajh/hpab053
   PubMed Web of Science ®Google Scholar
• Packer M. 2020. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 383(15):1413–1424. doi: 10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Solomon SD. 2022. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 387(12):1089–1098. doi: 10.1056/NEJMoa2206286
   PubMed Web of Science ®Google Scholar